FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000501281> ?p ?o ?g. }

• W2000501281 abstract "The patent expiry of innovative antibody drugs has provoked a great deal of concern over generic drugs. Reduction of medical costs by generics is undoubtedly beneficial to all countries, however, major issues about bioequivalence and immunogenicity remain incompletely addressed. The first draft guidance on the evaluation of biosimilarity was published by FDA in Feb 2012, in which emphasis was placed on the importance of evaluating minor structural differences that can significantly affect the potency and safety of biopharmaceuticals, with specific reference to glycosylation patterns on antibody drugs. We propose here a new method for validating the microheterogeneity of N-glycans on therapeutic antibodies. The continuous collision energy scanning of oligosaccharide-derived fragment ions (oxonium ions) illustrated both comprehensive structural information of glycans on glycopeptides and their quantitative abundance ratio simultaneously in a single analysis of a triple quadrupole mass spectrometer. We showed that oxonium ion m/z 138 could be a specific reporter ion for sensitive quantification of glycopeptides, regardless of glycan structures. Indeed the quantitation limit of glycopeptide was 30 attomole and, importantly, even very rare structural isomers were quantifiable, which existed only 0.1% of all glycoforms. We named this technology Energy Resolved Oxonium Ion Monitoring (Erexim) and utilized for the evaluation of lot-to-lot glycoform variations of monoclonal therapeutic antibodies trastuzumab and bevacizumab. The quantitative profiles of 4 lots (n = 4 each) revealed that N-glycans on both drugs showed gradually shortened tendency with time. Surprisingly some abundant glycoforms on both antibody drugs exhibited 10% changes between two continuous lots. We further applied Erexim technology to in-depth analysis of cetuximab glycosylation pattern, previously known to induce severe anaphylaxis. Our method successfully provided a comprehensive structural view of Fab- and Fc-glycans simultaneously in 30 minutes analysis, which uncovered lots of critical non-human type antigens only on the Fab region of cetuximab, such as Gal(α1-3)Gal or Neu5Gc structures. Hence in the process of future biosimilar approval, the Erexim technology we demonstrated herein has potential to define “how similar it is”. Citation Format: Koji Ueda, Atsuhiko Toyama, Taka-Aki Sato, Yusuke Nakamura, Hidewaki Nakagawa. Definition of biosimilars: Energy Resolved Oxonium Ion Monitoring (Erexim) technology grasps detailed N-glycan microheterogeneity on therapeutic antibodies. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3214. doi:10.1158/1538-7445.AM2013-3214 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend." @default.
• W2000501281 created "2016-06-24" @default.
• W2000501281 creator A5003219086 @default.
• W2000501281 creator A5031352565 @default.
• W2000501281 creator A5037795159 @default.
• W2000501281 creator A5081957766 @default.
• W2000501281 creator A5090972317 @default.
• W2000501281 date "2013-04-15" @default.
• W2000501281 modified "2023-09-25" @default.
• W2000501281 title "Abstract 3214: Definition of biosimilars: Energy Resolved Oxonium Ion Monitoring (Erexim) technology grasps detailed N-glycan microheterogeneity on therapeutic antibodies." @default.
• W2000501281 doi "https://doi.org/10.1158/1538-7445.am2013-3214" @default.
• W2000501281 hasPublicationYear "2013" @default.
• W2000501281 type Work @default.
• W2000501281 sameAs 2000501281 @default.
• W2000501281 citedByCount "1" @default.
• W2000501281 countsByYear W20005012812018 @default.
• W2000501281 crossrefType "proceedings-article" @default.
• W2000501281 hasAuthorship W2000501281A5003219086 @default.
• W2000501281 hasAuthorship W2000501281A5031352565 @default.
• W2000501281 hasAuthorship W2000501281A5037795159 @default.
• W2000501281 hasAuthorship W2000501281A5081957766 @default.
• W2000501281 hasAuthorship W2000501281A5090972317 @default.
• W2000501281 hasConcept C108625454 @default.
• W2000501281 hasConcept C145148216 @default.
• W2000501281 hasConcept C150903083 @default.
• W2000501281 hasConcept C159654299 @default.
• W2000501281 hasConcept C178386823 @default.
• W2000501281 hasConcept C178790620 @default.
• W2000501281 hasConcept C185592680 @default.
• W2000501281 hasConcept C203014093 @default.
• W2000501281 hasConcept C206212055 @default.
• W2000501281 hasConcept C2777313579 @default.
• W2000501281 hasConcept C2780868878 @default.
• W2000501281 hasConcept C542903549 @default.
• W2000501281 hasConcept C55493867 @default.
• W2000501281 hasConcept C59491497 @default.
• W2000501281 hasConcept C70721500 @default.
• W2000501281 hasConcept C71924100 @default.
• W2000501281 hasConcept C86803240 @default.
• W2000501281 hasConcept C98274493 @default.
• W2000501281 hasConceptScore W2000501281C108625454 @default.
• W2000501281 hasConceptScore W2000501281C145148216 @default.
• W2000501281 hasConceptScore W2000501281C150903083 @default.
• W2000501281 hasConceptScore W2000501281C159654299 @default.
• W2000501281 hasConceptScore W2000501281C178386823 @default.
• W2000501281 hasConceptScore W2000501281C178790620 @default.
• W2000501281 hasConceptScore W2000501281C185592680 @default.
• W2000501281 hasConceptScore W2000501281C203014093 @default.
• W2000501281 hasConceptScore W2000501281C206212055 @default.
• W2000501281 hasConceptScore W2000501281C2777313579 @default.
• W2000501281 hasConceptScore W2000501281C2780868878 @default.
• W2000501281 hasConceptScore W2000501281C542903549 @default.
• W2000501281 hasConceptScore W2000501281C55493867 @default.
• W2000501281 hasConceptScore W2000501281C59491497 @default.
• W2000501281 hasConceptScore W2000501281C70721500 @default.
• W2000501281 hasConceptScore W2000501281C71924100 @default.
• W2000501281 hasConceptScore W2000501281C86803240 @default.
• W2000501281 hasConceptScore W2000501281C98274493 @default.
• W2000501281 hasLocation W20005012811 @default.
• W2000501281 hasOpenAccess W2000501281 @default.
• W2000501281 hasPrimaryLocation W20005012811 @default.
• W2000501281 hasRelatedWork W2050727659 @default.
• W2000501281 hasRelatedWork W2058044390 @default.
• W2000501281 hasRelatedWork W2117080495 @default.
• W2000501281 hasRelatedWork W2397176959 @default.
• W2000501281 hasRelatedWork W2756221472 @default.
• W2000501281 hasRelatedWork W2768717631 @default.
• W2000501281 hasRelatedWork W2793293814 @default.
• W2000501281 hasRelatedWork W2793655673 @default.
• W2000501281 hasRelatedWork W2794607598 @default.
• W2000501281 hasRelatedWork W2885085301 @default.
• W2000501281 hasRelatedWork W2885734809 @default.
• W2000501281 hasRelatedWork W2989967683 @default.
• W2000501281 hasRelatedWork W2992732602 @default.
• W2000501281 hasRelatedWork W3014302285 @default.
• W2000501281 hasRelatedWork W3119024742 @default.
• W2000501281 hasRelatedWork W3174234591 @default.
• W2000501281 hasRelatedWork W3179718773 @default.
• W2000501281 hasRelatedWork W3198608577 @default.
• W2000501281 hasRelatedWork W3204525114 @default.
• W2000501281 hasRelatedWork W3209812556 @default.
• W2000501281 isParatext "false" @default.
• W2000501281 isRetracted "false" @default.
• W2000501281 magId "2000501281" @default.
• W2000501281 workType "article" @default.